Skip to main content

Table 2 Change from baseline in lung function parameters after 52 weeks

From: In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility

 PlaceboReslizumab52-week treatment difference (reslizumab vs placebo) (95% CI)p value
BaselineChange at 52 weeksBaselineChange at 52 weeks
≥ 400 EOS < 14% reversibility group
 N52426452  
 FEV1, mL2339 (107)265 (98)1945 (92)439 (105)174 (1 to 348)0.0493
 FEV1% predicted73.3 (2.6)6.7 (3.2)67.4 (2.2)13.8 (3.4)7.1 (1.4 to 12.7)0.0144
 FVC, mL3.5 (0.14)271 (121)2.9 (0.13)419 (129)148 (− 65 to 362)0.1714
 FEF25–75%, mLa1.7 (0.14)297 (133)1.3 (0.090)444 (141)147 (− 88 to 383)0.2172
Overall population excluding the ≥ 400 EOS < 14% reversibility group
 N424358413365  
 FEV1, mL1919 (35)130 (37)2018 (38)270 (36)139 (76 to 202)< 0.0001
 FEV1% predicted65.7 (0.94)4.7 (1.2)66.8 (1.0)9.1 (1.2)4.4 (2.3 to 6.5)< 0.0001
 FVC, mL2.9 (0.049)157 (46)3.1 (0.049)288 (45)131 (52 to 210)0.0013
 FEF25–75%, mLb1.7 (0.29)79 (53)1.4 (0.043)207 (51)128 (39 to 217)0.0047
  1. Baseline data are mean (SE). All change from baseline data are LS mean (SE)
  2. CI confidence interval, EOS blood eosinophil level, FEF2575% forced expiratory flow at 25–75% of pulmonary volume, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, LS least square, SE standard error
  3. aFEF25–75% data unavailable for n = 1 (placebo), n = 1 (reslizumab) patients
  4. bFEF25–75% data unavailable for n = 3 (placebo), n = 5 (reslizumab) patients